Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.5710
-0.0130 (-2.23%)
May 29, 2026, 10:37 AM EDT - Market open
Nexalin Technology Revenue
Nexalin Technology had revenue of $14.95K in the quarter ending March 31, 2026, a decrease of -63.55%. This brings the company's revenue in the last twelve months to $275.58K, up 110.26% year-over-year. In the year 2025, Nexalin Technology had annual revenue of $301.65K with 78.78% growth.
Revenue (ttm)
$275.58K
Revenue Growth
+110.26%
P/S Ratio
43.62
Revenue / Employee
$34,448
Employees
8
Market Cap
11.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 301.65K | 132.93K | 78.78% |
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.58M |
| Trinity Biotech | 43.79M |
| Lifeward | 20.92M |
| Vivos Therapeutics | 19.57M |
| Picard Medical | 5.47M |
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| IceCure Medical | 3.57M |
NXL News
- 8 days ago - Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - GlobeNewsWire
- 10 days ago - Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial - GlobeNewsWire
- 4 weeks ago - Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia - GlobeNewsWire
- 5 weeks ago - Nexalin Technology enters agreements to advance HALO Clarity trial - TheFly
- 5 weeks ago - Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment - GlobeNewsWire
- 6 weeks ago - Nexalin Technology advances FDA Alzheimer’s strategy - TheFly
- 6 weeks ago - Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China - GlobeNewsWire
- 6 weeks ago - Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 - GlobeNewsWire